Phaseline

Companies › Bright Minds Biosciences

Bright Minds Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BMB-101–Phase 2Absence Epilepsy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06401538BMB-101Phase 2Absence EpilepsyNeurologySep 2025

From the company's SEC filings

Cash of 6m CAD on 2024-09-30; operating cash outflow about 2m CAD a year; runway about 37 months at that burn, to Nov 2027

Private offerings reported to the SEC (Form D)

Specialist investors

Held by 14 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.